Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers
Overall, this indicates good feasibility, tolerability, and effectiveness of ADC therapies in the real-world setting.
Authors
- Sophia Huesmann
- Florin‐Andrei Taran
- Brigitte Rack (ORCID: https://orcid.org/0000-0002-7539-4839)
- Elena Leinert (ORCID: https://orcid.org/0000-0001-5795-3417)
- Dominik Dannehl (ORCID: https://orcid.org/0000-0002-7653-8283)
- Sara Y. Brucker (ORCID: https://orcid.org/0000-0001-5162-1542)
- Ingolf Juhasz‐Böss (ORCID: https://orcid.org/0000-0002-2178-6490)
- Andreas Hartkopf
- Fabienne Schochter (ORCID: https://orcid.org/0000-0003-3675-6494)
- Sabine Heublein (ORCID: https://orcid.org/0000-0002-5326-0186)
- Marie Louise Frevert (ORCID: https://orcid.org/0000-0002-6497-7051)
- Lea-Louise Volmer
- Alexander Englisch
- Tobias Engler (ORCID: https://orcid.org/0000-0002-8063-2053)
- Kristina Veselinovic (ORCID: https://orcid.org/0000-0002-2959-0580)
- Henning Schäffler
- Dorothee Jakob
- Kerstin Pfister (ORCID: https://orcid.org/0009-0002-2831-1401)
- Visnja Fink
- Wolfgang Janni
Institutions
- University of Freiburg (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Geburtshilfe und Frauenheilkunde
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1055/a-2375-5194
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70